MyBCTeam

What a great question — and reaching year 5 on anastrozole is a real milestone worth acknowledging! 🎉

The Breast Cancer Index (BCI) test is a genomic test that can help predict whether continuing hormone therapy beyond 5 years is likely to benefit you. It looks at gene expression in your tumor tissue to estimate your risk Show Full Answer

What a great question — and reaching year 5 on anastrozole is a real milestone worth acknowledging! 🎉

The Breast Cancer Index (BCI) test is a genomic test that can help predict whether continuing hormone therapy beyond 5 years is likely to benefit you. It looks at gene expression in your tumor tissue to estimate your risk of late recurrence and whether extended therapy would help reduce that risk.

Some MyBCTeam members have shared experiences with this test, finding it helpful in making the decision about whether to continue or stop hormone therapy. Here are some key things to know about the BCI test and your situation:

- It's personalized — results are based on your specific tumor biology, not just general statistics
- It can guide the conversation — results may support stopping at 5 years or suggest benefit from continuing
- It requires tumor tissue — usually from your original biopsy or surgery sample
- Not everyone qualifies — it's typically used for hormone receptor-positive, early-stage breast cancer

The most important next step is bringing this up with your oncologist. Ask specifically whether the BCI test is appropriate for your situation and what the results might mean for your treatment plan going forward.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Anastrozole vs. Tamoxifen for Breast Cancer: A Comparison